1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$10.63bn
- HK$8.44bn
- CNY2.03m
Brief: Ascletis Pharma Says IND Approval Of Oral Pd-L1 Small Molecule Inhibitor Asc61
Brief: Ascletis Pharma Announces IND Approval Of ASC10 For Monkeypox Indication By U.S. FDA
Brief: Ascletis Pharma Announces U.S. Ind Filing Of Oral 3Clpro Inhibitor Asc11 For Covid-19
Brief: Ascletis Pharma Announces U.S. IND Filing Of Oral Antiviral Asc10
Brief: Shanghai Public Health Clinical Center Completed Patient Enrollment In Clinical Study Of Pd-L1 Antibody Asc22 (Envafolimab) In Combination With Chidamide For Functional Cure Of HIV Infection
Brief: Ascletis Pharma Announces Ind Approval Of Oral Rdrp Inhibitor Asc10 For Covid-19 By China Nmpa
Brief: Ascletis Pharma Says IND Application Of Asc10 Oral Inhibitor Drug Targeting Rna-Dependent Rna Polymerase For Covid-19, Accepted By NMPA
Brief: Ascletis Pharma Announces U.S. Investigational New Drug Filing
Brief: Ascletis Pharma Inc - First Subject Dosed In Phase Ii Clinical Trial Of Asc22 (Envafolimab) For Immune Restoration/ Functional Cure Of Hiv-1 Infection
Brief: Ascletis Pharma Says Unit Got U.S. FDA Clearance For ASC42 To Initiate A Drug-Drug Interaction Study
Brief: Ascletis Pharma Announces U.S. IND Approval Of Asc22 (Envafolimab) For Immune Restoration Cure Of Hiv-1 Infected Patients
Brief: Ascletis Announces U.S. IND Approval Of ASC22 (Envafolimab) For Immune Restoration/Functional Cure Of HIV-1 Infected Patients
Brief: Ascletis Pharma Says 3Clpro Inhibitor ASC11 Demonstrated Potential To Be Effective Treatment For COVID-19
Brief: Ascletis Pharma Says Signed Agreement With China Meheco International
Brief: Ascletis Announces Submission Of Marketing Authorization Application For Ritonavir In Hong Kong
Brief: Ascletis Announces Completion Of Patient Enrollment In Phase II Clinical Trial Of Asc42
China's Ascletis submits drug marketing applications in Europe, stock soars
China's Ascletis jumps after positive data on drug against Omicron
Brief: Ascletis Pharma Announces Positive Data Of Oral Double Prodrug And Antiviral Nucleoside Analog Against Omicron Variant